NCT02940977 is a clinical trial of Blood draws in Prostatic Neoplasms, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT02940977?

NCT02940977 is sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT02940977?

Interventions in NCT02940977: Blood draws.

What condition does NCT02940977 study?

NCT02940977 studies Prostatic Neoplasms, Prostatic Adenoma.

Is NCT02940977 still recruiting?

NCT02940977 is currently status unknown. Last updated 10 July 2018.

Last reviewed 2018-07-10 · How we verify

NCT02940977

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique

Status unknown Last updated 10 July 2018

What this trial tests

trial testing Blood draws in Prostatic Neoplasms in 120 participants. Status unknown.

Timeline

1 October 2016

Primary endpoint
30 March 2019

30 March 2019

Quick facts

Lead sponsor	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 October 2016
Primary completion	30 March 2019
Estimated completion	30 March 2019
Sites	1 location across China

Drugs / interventions tested

Blood draws — full drug profile →

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Prostatic Adenoma — all drugs for Prostatic Adenoma →

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

18 and older, male only, with Prostatic Neoplasms or Prostatic Adenoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. To elucidate the role of CTC detection in the evaluation of risk level in PCa patients, and establish a mathematic model for predicting the pathological status. 2. To explore the possible subtle change in CTC condition after radical prostatectomy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Early Diagnosis of Prostate Cancer from the Perspective of Chinese Physicians.
Yu W, Zhou L. · · 2020 · cited 9× · PMID 32231732 · DOI 10.7150/jca.36697
Prospective Study of the Clinical Impact of Epithelial and Mesenchymal Circulating Tumor Cells in Localized Prostate Cancer.
Liu H, Ding J, Wu Y, Wu D, et al · · 2020 · cited 7× · PMID 32606948 · DOI 10.2147/cmar.s253997
Epithelial-Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical Implications.
Srinivasan D, Balakrishnan R, Chauhan A, Kumar J, et al · · 2025 · cited 5× · PMID 40895189 · DOI 10.1002/mco2.70333

Verify or expand the search:

Other trials of Blood draws

Trials testing the same drug.

NCT06424652 — Effect of Physiologic Insulin Administration on Cognition · NA · completed
NCT05595577 — Improving Exercise Capacity With a Tailored Physical Activity Intervention · NA · recruiting
NCT05204290 — Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab · EARLY_PHASE1 · terminated
NCT05091190 — Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers · NA · active not recruiting
NCT04037527 — Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities · Phase 1 · terminated

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07506811 — Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants · NA · not yet recruiting
NCT07441187 — Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type · not yet recruiting
NCT07375602 — A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children · recruiting
NCT07405658 — Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Ear · not yet recruiting
NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02940977 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Last refreshed: 10 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02940977.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing